PDC*line Pharma seeks to go public in Korea Belgian-French clinical-stage biotech firm to become first European company listed here
Translated by Kim So-in 공개 2022-05-23 08:08:14
이 기사는 2022년 05월 23일 08:06 thebell 에 표출된 기사입니다.
PDC*line Pharma is seeking to go public in South Korea next year to become the first European company to list its shares here.Founded in 2014 as a spin-off from the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of plasmacytoid dendritic cells (PDC*line).
The company aims to go public in Korea next year, according to industry sources on Friday. There are two overseas companies listed on the country’s main bourse Kospi and 21 on the junior Kosdaq market, according to Korea Exchange.
Most recently, U.S.-based NeoImmuneTech and Singapore-based Prestige Biopharma made there market debuts here.
All foreign biotech firms listed on the domestic stock market are their Korean subsidiaries. They all collaborated with domestic personnel during their listing processes. In PDC*line Pharma’s case, the Belgian-French biotech company itself is going public.
The company has hired Mirae Asset Securities to handle the IPO process. PDC*line Pharma is considering to carry out its listing via the country’s special track like other domestic biotech firms did.
PDC*line Pharma completed its Series B2 round of financing in December 2021, raising a total of €17.5 million (23 billion won) from Belgian and South Korean investors.
The financing round was led by Korea Investment Partners and involved a syndicate of new South Korean investors in life sciences: Alpha Holdings, Brain Asset Management and Hansong Neotech.
Existing investors also participated: Noshaq Group, Sambrinvest, SFPI-FPIM (the Belgian Federal Holding and Investment Company) and SRIW (The Regional Investment Company of Wallonia). The proceeds will primarily be used to fund company’s phase I/II trial with PDC*lung01, a vaccine candidate for lung cancer. (Reporting by Joon-woo Nam)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
- 피디씨라인파마, 유럽기업 최초 '한국 상장' 도전
- Korean biotech startups wary of investing in IL-2 development
- Daewoong Pharmaceutical establishes first investment entity in U.S.
- HK Inno.N out-licenses GERD drug K-CAB to US pharma company
- GS Group accelerates investments in healthcare and pharma
- Huons BioPharma attracts $132 mil from China's Imeik Technology Development
best clicks
최신뉴스 in 전체기사
-
- 수출입은행, 상반기 출자사업에 14곳 출사표
- 카카오, 2억달러 교환사채 발행 '공식화'
- [Red & Blue]수급 몰리는 피제이메탈, 알루미늄 시세 급등 '수혜'
- 이에이트, 가천대·길병원과 '디지털 트윈 병원' 구축 MOU
- [멀티플렉스 재무 점검]베트남만 남은 롯데시네마 해외사업
- [뮤지컬 제작사 열전]EMK컴퍼니, 고속성장 비결은 '대기업과 10년 동맹'
- 모트롤 인수 추진하는 두산그룹, 3년 전과 달라진 건
- [LG화학의 변신]패착된 NCC 증설, 자산 유동화 '제값 받기' 관건
- [캐시플로 모니터]포스코인터 '조단위 투자' 거뜬한 현금창출력
- [항공사 기단 2.0]'공격 확대' 에어프레미아·이스타, 매출·리스 줄다리기